Posted by Michael Wonder on 23 Nov 2022
BioMarin announces advancements in FDA review of Roctavian (valoctocogene roxaparvovec) for adults with severe haemophilia A
23 November 2022 - FDA no longer plans to hold an advisory committee meeting, as previously planned, to discuss the biologics license application.
BioMarin Pharmaceutical announced advancements in the US FDA review of the biologics license application of Roctavian (valoctocogene roxaparvovec AAV gene therapy) for adults with severe haemophilia A.
